

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number  
WO 03/078407 A1

(51) International Patent Classification: C07D 253/06,  
C07C 277/08, 281/18

(74) Agent: HUGHES, Ivor, M.; Suite 200, 175 Commerce  
Valley Drive West, Thornhill, Ontario L3T 7P6 (CA).

(21) International Application Number: PCT/CA02/01926

(22) International Filing Date:  
18 December 2002 (18.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2,366,521 24 December 2001 (24.12.2001) CA

(71) Applicant (for all designated States except US): BRANT-  
FORD CHEMICALS INC. [CA/CA]; 34 Spalding Drive,  
Brantford, Ontario N3T 6B8 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GUNTOORI,  
Bhaskar, Reddy [CA/CA]; 26 Sudds Lane, Brantford,  
Ontario N3T 6M5 (CA). CHE, Daqing [CN/CA]; 31  
Thornton Drive, Brantford, Ontario N3R 7L6 (CA).  
MURTHY, Keshava, K., S. [CA/CA]; 43 Hobart Cres-  
cent, Brantford, Ontario N3P 1V5 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.



(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: A NEW AND EFFICIENT PROCESS FOR THE PREPARATION OF LAMOTRIGINE AND RELATED  
3,5-DIAMINO-6-SUBSTITUTED-1,2,4-TRIAZINES



(57) Abstract: A process for the manufacture of 3,5-diamino-6-substituted-1,2,4-triazines is disclosed which comprises the steps of: (a) reacting a compound of formula (II) with aminoguanidine salts, (b) dehydrating the compound obtained to form a compound of formula (IV), and (c) cyclization of the compound of formula (IV) into a 3,5-diamino-6-substituted-1,2,4-triazine compound of formula (I) or into a hydrated form thereof.

WO 03/078407 A1

JC05 Rec'd PCT/PTO 16 MAR 2005

TITLE OF THE INVENTION


A NEW AND EFFICIENT PROCESS FOR THE PREPARATION OF LAMOTRIGINE AND RELATED 3,5-DIAMINO-6-SUBSTITUTED-1,2,4-TRIAZINES

FIELD OF THE INVENTION

The present invention relates to novel processes for the production of 3,5-diamino-6-substituted-1,2,4-triazines in general, and the antiepileptic agent Lamotrigine in particular.

BACKGROUND OF THE INVENTION

Lamotrigine 1, 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, is an antiepileptic drug, and its analogues were first disclosed in British Patent No. 759,014 (1956). Subsequently, Lamotrigine and its analogues were described in Canadian Patent Nos. 1,112,643 and 1,133,938, and in United States Patent No. 4,602,017. Processes for the preparation of Lamotrigine are also disclosed in international publications and patents WO 96/20934, WO 96/20935, WO 00/35888 and European Patent No. 963,980.




**Lamotrigine 1**

The process (as disclosed in Canadian Patent Nos. 1,112,643 and 1,133,938, United States Patent No. 4,602,017 and in British Patent No. 759,014) for the preparation of Lamotrigine involves reaction of 2,3-dichlorobenzoyl cyanide 2 and aminoguanidine bicarbonate in dimethylsulfoxide and 8N aqueous nitric acid (scheme 1). The above process uses drastic conditions (20 eq. 8N HNO<sub>3</sub>),

excess reagents and requires 7 days for completion of the reaction. The overall yield of the process from 2,3-dichlorobenzoyl cyanide is 15.6%.

Scheme 1




The process reported in WO 00/35888 for this reaction uses H<sub>2</sub>SO<sub>4</sub> instead of 8N HNO<sub>3</sub>. However, it also suffers from lower yield (40%) and longer reaction time (2.5 days). The process also uses a large excess (~11 times) of sulfuric acid.

It is accordingly an object of the present invention to provide an improved process for the manufacture of lamotrigine which overcome the problems associated with poor efficiency described in the prior art. More broadly, it is an object of the present invention to provide novel processes for the production of 3,5-diamino-6-substituted-1,2,4-triazines.


#### SUMMARY OF THE INVENTION

In accordance with one aspect of the present invention, there is provided a process for the manufacture of an intermediate compound of formula IV



formula IV


useful for manufacturing 3,5-diamino-6-substituted-1,2,4-triazines, wherein R is an optionally substituted C<sub>1</sub>-C<sub>4</sub> alkyl or aryl group, which process comprises reacting a compound of formula II:



**formula II**

with aminoguanidine in the presence of an acid in an organic solvent under anhydrous conditions followed by treatment with a dehydrating reagent.


In accordance with another aspect of the present invention there is provided a process for the manufacture of 3,5-diamino-6-substituted-1,2,4-triazines of formula I:



**formula I**


comprising the steps of:

- (a) reacting a compound of formula (II):




**formula II**

with aminoguanidine salts, or equivalent thereof, in the presence of an acid in an organic solvent under anhydrous conditions to form a cyanohydrin of formula III:



formula III

- (b) dehydrating the cyanohydrin of formula III to form a compound of formula IV by treatment with a dehydrating reagent,



formula IV

and


- (c) cyclization of the compound of formula IV into a 3,5-diamino-6-substituted-1,2,4-triazine of compound of formula I or into a hydrated form thereof.

Suitably the substituted C<sub>1</sub>-C<sub>4</sub> alkyl group is methyl, ethyl, propyl or butyl and the substituted aryl group is preferably 2,3-dichlorophenyl.

The process of the present invention provides a high yielding and cost-effective process for the preparation of 3,5-diamino-6-substituted-1,2,4-triazines in general and Lamotrigine in particular. This result is obtained through the use of an additive, namely a dehydrating agent, such as thionyl chloride, POCl<sub>3</sub> or PCl<sub>5</sub>, and by employing organic acid in combination with a polar organic solvent, which stabilizes the cyanohydrin of formula III. The cyanohydrin of formula III upon addition of a dehydrating agent affords the intermediate iminoguanidine of formula IV (scheme 2).

The acid used in this process can be dry organosulfonic acids such as methanesulfonic acid or para-toluenesulfonic acid, either in combination with dry polar organic solvents, such as dimethylformamide (DMF), N-methyl-2-pyrrolidinone (NMP) or dimethylsulfoxide (DMSO), or combinations of a polar solvent with nonpolar solvents such as tetrahydrofuran (THF). The dehydrating reagents used in the process can be  $\text{SOCl}_2$ ,  $\text{POCl}_3$  or  $\text{PCl}_5$ , oxalyl chloride, phosgene or equivalents thereof.

Scheme 2



The process, as shown in Scheme 2, involves the reaction of aryl cyanide, preferably 2,3-dichlorobenzoyl cyanide 2 (in which R = 2,3-dichlorophenyl), with an organic acid, for example para-toluenesulfonic acid or methanesulfonic acid, and dry organic solvents, for example DMSO, NMP or DMF, at suitable temperatures to form an intermediate of formula III. The reaction mixture is treated with dehydrates for example  $\text{SOCl}_2$ ,  $\text{POCl}_3$  or  $\text{PCl}_5$ , oxalyl chloride, phosgene or equivalent thereof at a suitable temperature to form the iminoguanidine of formula IV. The iminoguanidine salt in the reaction mixture is cyclized upon basification and heating. The

iminoguanidine salt can be basified and isolated by filtration. The isolated iminoguanidine can be cyclized to form Lamotrigine using a base (such as NaOH, NH<sub>3</sub> or KOH) in a protic solvent (such as methanol, ethanol, isopropanol or water). Lamotrigine 1 can be isolated as the monohydrate when the cyclization of the intermediate is carried out using base and isopropanol/water mixture or NMP/water. The lamotrigine monohydrate is a new compound and is further characterized in having the following peaks in powder X-ray diffraction pattern at an angle of two theta (2θ) is found to be: 10.34, 11.53, 12.46, 13.36, 13.86, 14.15, 14.94, 16.43, 16.65, 17.44, 17.97, 18.77, 18.91, 19.11, 19.52, 20.58, 22.11, 22.31, 23.09, 23.61, 24.18, 24.99, 25.52, 26.31, 26.83, 27.68, 28.53, 29.07, 29.24, 29.86, 30.09, 30.63, 31.01, 31.37, 31.78, 32.82, 33.25, 34.35, 34.96, 36.23, 36.92, 37.97, 38.60, 38.90. The positions of the peaks in powder X-ray diffraction pattern studies of anhydrous lamotrigine at an angle of two theta (2θ) to be 9.80, 11.39, 12.46, 13.29, 13.86, 14.13, 15.62, 16.66, 17.44, 17.97, 19.54, 20.56, 22.30, 22.89, 23.61, 24.81, 25.50, 26.31, 26.74, 27.87, 28.42, 28.86, 29.38, 29.66, 30.95, 31.66, 32.59, 33.23, 33.61, 33.83, 34.21, 35.20, 36.27, 37.16, 37.90, 38.35, 38.92, 39.17, 39.45.

The overall yield of lamotrigine is high (molar yield: 80 ~ 85%). The above described process is very cost-effective, operationally simple and completed in a short time period (6 to 10 hours).

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is the powder X-ray diffraction pattern of lamotrigine monohydrate.

Figure 2 is a differential scanning calorimetry thermogram (DSC) of lamotrigine monohydrate.

Figure 3 is a Fourier transform infrared spectrum (FTIR) of lamotrigine monohydrate.

Figure 4 is the powder X-ray diffraction pattern of anhydrous lamotrigine.

Figure 5 is a differential scanning calorimetry thermogram (DSC) of anhydrous lamotrigine.

Figure 6 is a Fourier transform infrared spectrum (FTIR) of anhydrous lamotrigine.

The following examples serve to illustrate embodiments of the present invention in a manner in which they can be practiced but, as such, should not be considered in a limiting sense.

## EXAMPLES

### Procedure I

To a round bottomed flask was added aminoguanidine hydrochloride (116.1 g, 1.05 mol) and dimethylformamide (900 mL). To this mixture was added methanesulfonic acid (130.4 g, 1.36 mol) followed by adding 2,3-dichlorobenzoylcyanide (150.0 g, 0.75 mol). The reaction mixture was stirred for 1 hour and then the dehydrating reagent, thionyl chloride, (45.2g, 0.38 mol) was added. The reaction mixture was stirred for another hour and then basified with KOH solution (4N). The precipitate was filtered and washed with water.

Yield: 401.3 g damp cake (KF = 39.2%).

Analytically pure sample of the intermediate is prepared as following:

20.0 g of the damp cake was suspended in 60 ml MeOH and stirred at room temperature for 3 hours. The solid was filtered and dried in vacuum at room temperature to give 5.4 g analytic pure iminoguanidine as a yellow solid.

m.p.: 179 ~ 180° C (corrected).

MS (m/z): 256.3 [M<sup>+</sup>]



IR: 3491.8; 3457.1 (Amine N-H stretching); 2207.5 (CN stretching); 1681.9 (Imine C=N stretching); 1055.5 (C<sub>aryl</sub>-Cl stretching).

<sup>1</sup>H-NMR (300 MHz, DMSO-D<sub>6</sub>): 7.66 (ad, J = 7.9 Hz, 2H), 7.41 (dd, J = 7.9; 7.9 Hz, 1H), 6.70 (br s, NH<sub>2</sub>).

<sup>13</sup>C-NMR (75 MHz, DMSO-D<sub>6</sub>): 163.6, 135.3, 132.4, 130.0, 129.5, 129.0, 128.2, 114.4, 113.8.

Elemental analysis:	C	H	N
Calculated:	42.21	2.76	27.35
Found:	42.10	2.49	27.69

#### Procedure II:

A round bottomed flask was charged with iminoguanidine (401.3 g from procedure I), isopropanol (1000.0 ml) and KOH (85%, 12.0 g, 0.18 mol). The reaction mixture was refluxed for 3 hours. Isopropanol was distilled and water (800 ml) was added. The reaction mixture was stirred for 3 hours, the solid was filtered and washed with water. The damp cake is dried under vacuum to yield 168.5 grams of lamotrigine monohydrate as crystalline solid (82% based on 2,3-dichlorobenzoyl cyanide).

#### Procedure III (without isolation of intermediate of formula IV):

To a round bottomed flask was added aminoguanidine hydrochloride (116.1 g, 1.05 mol) and dimethylformamide (900 ml). To this mixture was added methanesulfonic acid (130.4 g, 1.36 mol) followed by 2,3-dichlorobenzoyl cyanide (150.0 g, 0.75 mol). The reaction mixture was stirred for 1 hour and then dehydrating reagent thionyl chloride (45.2g, 0.38 mol) was added slowly. The reaction mixture was stirred for another hour and then basified with KOH solution (4 N). The Reaction mixture was heated under reflux (100 ~ 105° C) for 3 ~ 4 hours and cooled slowly to room temperature. The solid was filtered and washed with water. After drying, 160.7g of lamotrigine

monohydrate as a crystalline solid (78% based on 2,3-dichlorobenzoyl cyanide) was obtained.

See also FIG. 1, 2, 3.

Karl Fischer (water content): 5.92 ~ 6.03%

DSC: 106.86, 216.65° C (onset).

MS (m/z): 256.3 [M<sup>+</sup>]

IR: 3496.9; 3450.3; 3338.5; 3211.0; 1658.7; 1524.0; 1328.8; 1027.1.

<sup>1</sup>H-NMR (300 MHz, DMSO-D<sub>6</sub>): 7.66 (ad, J = 7.9 Hz, 2H), 7.41 (dd, J = 7.9; 7.9 Hz, 1H), 6.70 (br s, NH<sub>2</sub>).

<sup>13</sup>C-NMR (75 MHz, DMSO-D<sub>6</sub>): 163.6, 135.3, 132.4, 130.0, 129.5, 129.0, 128.2, 114.4, 113.8.

Procedure IV (preparation of anhydrous lamotrigine from lamotrigine monohydrate):

150 g lamotrigine monohydrate (from procedure II or III) was recrystallized in 900 mL isopropanol giving 132 g (94%) of anhydrous lamotrigine as a crystalline solid.

See also FIG. 4, 5, 6.

m.p.: 216 ~ 217° C (corrected).

MS (m/z): 256.3 [M<sup>+</sup>]


<sup>1</sup>H-NMR (300 MHz, DMSO-D<sub>6</sub>): 7.69 (dd, J = 1.7; 7.9 Hz, 1H), 7.43 (dd, J = 7.9; 7.6 Hz, 1H), 7.35 (dd, J = 1.7; 7.6 Hz, 1H), 6.70 (br s, NH<sub>2</sub>), 6.44 (br s, NH<sub>2</sub>).

<sup>13</sup>C-NMR (75 MHz, DMSO-D<sub>6</sub>): 162.1, 154.1, 138.3, 136.8, 132.0, 131.6, 130.6, 128.5.

Elemental analysis:	C	H	N
Calculated:	42.21	2.76	27.35
Found:	42.10	2.58	27.46

The embodiments of the invention in which an exclusive property or privilege is claimed are as following:


1. A process for the manufacture of 3,5-diamino-6-substituted-1,2,4-triazines of formula (I):



**formula 1**


wherein R is optionally substituted C<sub>1</sub>-C<sub>4</sub> alkyl or aryl group, the process comprising the steps of:

- (a) reacting a compound of formula (II):




**formula II**

with aminoguanidine in the presence of an organic sulphonic acid in an organic solvent under anhydrous conditions to form a cyanohydrin of formula III:



**formula III**

- (b) dehydrating the cyanohydrin of formula III to form a compound of formula IV by using a dehydrating reagent,




formula IV

and

- (c) cyclization of the compound of formula IV into a 3,5-diamino-6-substituted-1,2,4-triazine compound of formula I or into a hydrated form thereof.
2. The process of Claim 1 wherein the aryl group is 2,3-dichlorophenyl.
  3. The process of Claim 1 wherein the 3,5-diamino-6-substituted-1,2,4-triazine produced is 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine.
  4. The process of Claim 1 wherein the hydrated form is 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine monohydrate.
  5. The process of Claim 1, 2, 3 or 4 wherein said organic solvent is selected from the group consisting of DMF, NMP, and DMSO and mixtures thereof.
  6. The process of claim 1, 2, 3 or 4 wherein said organic sulphonic acid is selected from the group consisting of methanesulphonic acid and para-toluenesulfonic acid.
  7. The process of claim 1, 2, 3 or 4 wherein the dehydrating reagent is selected from the group consisting of  $\text{SOCl}_2$ ,  $\text{POCl}_3$ ,  $(\text{COCl})_2$ ,  $\text{PCl}_5$  and phosgene.


8. The process of claim 6 wherein the dehydrating reagent is  $\text{SOCl}_2$ .
9. The process of claim 6 wherein the dehydrating reagent is  $\text{POCl}_3$ .
10. The process of claim 6 wherein the dehydrating reagent is  $(\text{COCl})_2$ .
11. The process of claim 6 wherein the dehydrating reagent is  $\text{PCl}_5$ .
12. The process of claim 6 wherein the dehydrating reagent is phosgene.
13. The process of claim 6 wherein the organic solvent is selected from the group consisting of DMF, NMP and DMSO and mixtures thereof.
14. The process of claim 13 wherein said organic solvent is mixed with a non-polar solvent.
15. A process for the manufacture of compound of formula (IV):



**formula IV**

wherein R is optionally substituted  $\text{C}_1\text{-C}_4$  alkyl or aryl group, the process comprising:

reacting compound of formula (II):



**formula II**

with aminoguanidine in the presence of an organic sulphonic acid in an organic solvent under anhydrous conditions followed by treatment with a dehydrating reagent.

16. The process of Claim 15 wherein the aryl group is 2,3-dichlorophenyl.
17. The process of Claim 15 or 16 wherein said organic sulphonic acid is selected from the group consisting of methanesulfonic acid and para-toluenesulfonic acid.
18. The process of claim 17 wherein said organic solvent is mixed with a non-polar solvent.
19. The process of claim 15 or 16 wherein the dehydrating reagent is selected from the group consisting of  $\text{SOCl}_2$ ,  $\text{POCl}_3$ ,  $(\text{COCl})_2$ ,  $\text{PCl}_5$ , and phosgene.
20. The process of claim 17 wherein the dehydrating reagent is  $\text{SOCl}_2$ .
21. The process of claim 17 wherein the dehydrating reagent is  $\text{POCl}_3$ .
22. The process of claim 17 wherein the dehydrating reagent is  $(\text{COCl})_2$ .
23. The process of claim 17 wherein the dehydrating reagent is  $\text{PCl}_5$ .
24. The process of claim 17 wherein the dehydrating reagent is phosgene.
25. The process of claim 19 wherein the organic solvent is selected from the group consisting of DMF, NMP and DMSO and mixtures thereof.
26. The process of claim 18 wherein said organic solvent is selected from the group consisting of DMF, NMP and DMSO and mixtures thereof.

## FIGURE 1




FIG. 1: Powder X-ray diffraction pattern analysis of lamotrigine monohydrate



## FIGURE 2




FIG. 2: Differential scanning calorimetry thermogram (DSC) of lamotrigine monohydrate

## FIGURE 3




FIG. 3: Fourier transform infrared spectrum (FTIR) of lamotrigine monohydrate

FIGURE 4




FIG. 4: Powder X-ray diffraction pattern analysis of anhydrous lamotrigine

## FIGURE 5




FIG. 5: Differential scanning calorimetry thermogram (DSC) of anhydrous lamotrigine


**FIGURE 6**

FIG. 6: Fourier transform infrared spectrum (FTIR) of anhydrous lamotrigine

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/01926

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D253/06 C07C277/08 C07C281/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, WPI Data, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 1 127 873 A (CHEMAGIS LTD) 29 August 2001 (2001-08-29) the whole document; in particular, example 1 and page 3, line 55 - page 4, line 34 ---	1-26
A	WO 92 20934 A (COORS BREWING CO) 26 November 1992 (1992-11-26) cited in the application the whole document; in particular, reference example 2, example 7, page 5, lines 13-27 and page 7, line 26 - page 8, line 2 --- -/--	1-26

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

7 March 2003

Date of mailing of the international search report

21/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fink, D

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 02/01926

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SETTEPANI, JOSEPH A. ET AL: "Heterocyclic amines. A convenient synthesis of 3,5-diamino-1,2,4-triazine derivatives" J. HETEROCYCLIC CHEM. , vol. 3, no. 2, 1966, pages 188-190, XP002233812</p> <p>the whole document; in particular, page 190, second paragraph and page 188, column 1, last paragraph - column 2, first paragraph</p> <p>-----</p>	1-26

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CN02/01926

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 1127873	A	29-08-2001	CA	2337280 A1		25-08-2001
			EP	1127873 A2		29-08-2001
			HU	0100740 A2		28-11-2001
			PL	346034 A1		27-08-2001
			US	2001025118 A1		27-09-2001
WO 9220934	A	26-11-1992	US	5172981 A		22-12-1992
			CA	2108976 A1		23-11-1992
			EP	0584225 A1		02-03-1994
			JP	6511534 T		22-12-1994
			WO	9220934 A1		26-11-1992